Caroline Palomeque
Stock Analyst at Maxim Group
(2.63)
# 1,944
Out of 4,820 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $3.00 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $29.38 | +100.82% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $168.97 | -8.86% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $59.25 | -2.11% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $159.50 | +4.08% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $15.51 | +151.45% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.21 | +562.32% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $9.40 | +325.53% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.00
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $29.38
Upside: +100.82%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $168.97
Upside: -8.86%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $59.25
Upside: -2.11%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $159.50
Upside: +4.08%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $15.51
Upside: +151.45%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.21
Upside: +562.32%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $9.40
Upside: +325.53%